303 related articles for article (PubMed ID: 36003379)
1. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
Front Immunol; 2022; 13():950134. PubMed ID: 36003379
[TBL] [Abstract][Full Text] [Related]
2. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.
Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G
Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylating agents (HMAs) show benefit in AML rather than in intermediate/high-risk MDS based on genetic mutations in epigenetic modification (EMMs): from a retrospective study.
Wang R; Xu Y; Wang B; Wang H; Wang M; Jing Y; Gao X; Yu L
Ann Hematol; 2024 Jan; 103(1):61-71. PubMed ID: 37926751
[TBL] [Abstract][Full Text] [Related]
4. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
[TBL] [Abstract][Full Text] [Related]
5. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation.
Ørskov AD; Treppendahl MB; Skovbo A; Holm MS; Friis LS; Hokland M; Grønbæk K
Oncotarget; 2015 Apr; 6(11):9612-26. PubMed ID: 25823822
[TBL] [Abstract][Full Text] [Related]
7. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
Zeidan AM; Salimi T; Epstein RS
Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents.
Festuccia M; Baker K; Gooley TA; Sandmaier BM; Deeg HJ; Scott BL
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1509-1514. PubMed ID: 28600031
[TBL] [Abstract][Full Text] [Related]
9. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
10. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
11. Response to hypomethylating agents improves long-term outcomes for lower-risk patients with myelodysplastic syndrome in case-matched cohorts.
Baek DW; Lee YJ; Kim H; Ahn SY; Ahn JS; Shin HJ; Lee WS; Lee SM; Song IC; Lee HS; Park SW; Choi Y; Cho YY; Bae SH; Kim HJ; Sohn SK; Moon JH
Ann Hematol; 2018 Dec; 97(12):2309-2317. PubMed ID: 30073392
[TBL] [Abstract][Full Text] [Related]
12. Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies.
Pan T; Qi J; You T; Yang L; Wu D; Han Y; Zhu L
Leuk Res; 2018 Aug; 71():13-24. PubMed ID: 29936305
[TBL] [Abstract][Full Text] [Related]
13. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints.
Hidalgo-López JE; Kanagal-Shamanna R; Quesada AE; Thakral B; Hu Z; Mitsuhashi T; Yabe M; Garcia-Manero G; Bueso-Ramos CE
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S16-S25. PubMed ID: 28760297
[TBL] [Abstract][Full Text] [Related]
14. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
15. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia.
Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L
Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933
[TBL] [Abstract][Full Text] [Related]
16. When is the optimal timing for allogeneic transplantation in the case of MDS patients treated with hypomethylating agents?
Sohn SK; Moon JH
Expert Rev Hematol; 2013 Aug; 6(4):389-95. PubMed ID: 23991925
[TBL] [Abstract][Full Text] [Related]
17. Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes?
Bewersdorf JP; Zeidan AM
Leuk Lymphoma; 2020 Oct; 61(10):2295-2312. PubMed ID: 32421403
[TBL] [Abstract][Full Text] [Related]
18. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents.
Pophali P; Desai SR; Shastri A
Curr Hematol Malig Rep; 2023 Jun; 18(3):56-67. PubMed ID: 37052811
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments for myelodysplastic syndromes: Biological rationales and clinical translation.
Rodriguez-Sevilla JJ; Adema V; Garcia-Manero G; Colla S
Cell Rep Med; 2023 Feb; 4(2):100940. PubMed ID: 36787738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]